- 23 apr.- 18:44

Schlumberger comunica i risultati registrati nel primo trimestre del 2021

Business Wire.
  • Utili registrati a livello mondiale pari a 5,2 miliardi di dollari
  • Utili internazionali pari a 4,2 miliardi di dollari e a 972 milioni di dollari per il Nord America
  • Rendimento per azione pari a 0,21 dollari
  • Il flusso di cassa generato dalle operazioni ammonta a 429 milioni di dollari, mentre il flusso di cassa libero è risultato pari a 159 milioni di dollari
  • Approvato dal Consiglio di amministrazione un dividendo trimestrale in contanti di 0,125 dollari per azione
- 23 apr.- 16:05

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021

Business Wire.
  • Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients1
  • Patients enrolled in ECZTRA 1 and 2 parent trials who continued into ECZTEND have now been treated with tralokinumab for two years1
  • The overall safety profile of tralokinumab was consistent with that observed in the parent trials1
- 23 apr.- 15:11

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

Business Wire.
  • New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to fight infections and develop protective antibodies from vaccines
  • Independent study from Israel showed MAVENCLAD-treated patients receiving COVID-19 vaccine were able to mount antibody response similar to that of healthy subjects
  • Updated safety data show MAVENCLAD-treated patients with confirmed or suspected COVID-19 continue to have a disease course similar to the general population
- 23 apr.- 14:16

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis

Business Wire.

NOT FOR DISTRIBUTION IN THE UK OR IRELAND

  • If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms1,2
  • The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
- 23 apr.- 12:50

Schlumberger Announces First-Quarter 2021 Results

Business Wire.
  • Worldwide revenue was $5.2 billion
  • International revenue was $4.2 billion and North America revenue was $972 million
  • EPS was $0.21
  • Cash flow from operations was $429 million and free cash flow was $159 million
  • Board approved quarterly cash dividend of $0.125 per share

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni


Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Poste News
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Real Estate

Criptovalute news


Modifica consenso Cookie